A Phase 3 interventional study of Olezarsen in Severe Hypertriglyceridemia, sponsored by Ionis Pharmaceuticals, Inc.. Active, not recruiting at 262 sites in 33 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-01.
Sponsored by Ionis Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc. — 1 open to participants now, 2 under way, 1 of them phase 3. Hypertriglyceridemia · Ionis Pharmaceuticals, Inc..
Among the 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc., this one is the 2nd largest by enrollment, is one of 4 that started in 2022, is one of 5 in phase 3, and was the 11th registered.
324 studies on the registry are indexed under Hypertriglyceridemia; 38 are open to participants now.
Browse Hypertriglyceridemia studies →1 of the 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc. is open now, in 2 countries. Recruiting first, the newest first:
Ionis Pharmaceuticals, Inc. · Sites in United States, Canada
Ages 18+
By country, each count listing its studies:
Of the 22 Hypertriglyceridemia studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 4 started in 2022.
This study's enrollment of 885 is above the median of 66 across 288 interventional studies indexed under Hypertriglyceridemia.
Median enrollment 114 across the 12 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ionis Pharmaceuticals, Inc. is the lead sponsor of 118 studies on the registry; 10 are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 22 (45%) have results posted.
2 of the studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05681351Phase 3Ionis Pharmaceuticals, Inc.CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) | 2027-03 |
| NCT07604974Ionis Pharmaceuticals, Inc.A Study to Assess the Safety, Tolerability and Efficacy of ION775 | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.
This is a multi-center, open-label extension (OLE) study of approximately 800 participants with SHTG who would be rolled over from studies ISIS 678354-CS5 (NCT05079919) or ISIS 678354-CS6 (NCT05552326). Day 1 of this study may be same as the Week 53 visit of either ISIS 678354-CS5 or ISIS 678354-CS6, as applicable. Participants will receive olezarsen during the 157-week treatment period. The study will include a 31-day qualification Period, a 157-week treatment period, and a 13-week post-treatment period.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other Inclusion/Exclusion criteria may apply.
Participants who completed either ISIS 678354-CS5 (NCT05079919) or ISIS 678354-CS6 (NCT05552326) study would be enrolled to receive olezarsen, subcutaneous (SC) injection, once every 4 weeks from Week 1 through Week 153.
Drug: Olezarsen
Administered as SC injection.
Also known as: AKCEA-APOCIII-LRx, ISIS 678354
Proportion of Participants With Change in Clinical Laboratory Values From Baseline to Week 53, From Baseline to Week 105, and From Baseline to Week 157
Time frame: Baseline up to Week 157
Proportion of Participants Who Experience Adverse Events (AEs)
Time frame: Baseline up to Week 157
Proportion of Participants Who Use Concomitant Medications
Time frame: Baseline up to Week 157
Showing the first 100 of 262 sites across 33 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Ionis may share anonymized individual participant data, aggregated clinical data, and other types of data that support the results in this study. Data requests from qualified researchers will be considered once all three of the following criteria are met: (1) 12 months from marketing approval of the study drug in both the United States and European Union; (2) 18 months from conclusion of the study; and (3) 6 months from publication of study article. Access would be via a secure environment and is contingent upon approval of a research proposal and entry into an appropriate data use agreement. Requests to access data can be submitted via the website https://vivli.org/ourmember/ionis/.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Dec 2022 (actual). Primary completion is estimated for Mar 2027, 51 months after the start.
Of 28 industry-sponsored phase 3 interventional studies under Hypertriglyceridemia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 31. This study's planned 51 months is above that.
Counting every sponsor, half of 29 studies reached it within 24 months; a quarter within 18 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olezarsen